← Back to Clinical Trials
Recruiting NCT06739005

NCT06739005 AI Model for Assessing Cardiac Surgeons' Techniques

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06739005
Status Recruiting
Phase
Sponsor China National Center for Cardiovascular Diseases
Condition CABG-patients
Study Type OBSERVATIONAL
Enrollment 284 participants
Start Date 2025-01-09
Primary Completion 2026-12

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 284 participants in total. It began in 2025-01-09 with a primary completion date of 2026-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this study aims to investigate the use of artificial intelligence to analyze and evaluate the characteristics and proficiency of surgeons during vascular anastomosis in coronary artery bypass grafting (CABG) procedures. The main question it aims to answer is: Consistency assessment between AI evaluation scores and human expert evaluation scores for surgeons during left anterior descending (LAD) artery anastomosis.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Undergoing internal mammary artery-to-left anterior descending artery bypass grafting * First-time recipient of isolated CABG surgery * Signed written informed consent Exclusion Criteria: * Patients with acute coronary syndrome * Patients with contraindications to coronary CT angiography or coronary angiography * Patients with renal insufficiency or active liver disease, including those with persistently elevated serum transaminases of unknown cause or any serum transaminase levels exceeding three times the upper limit of normal.

Contact & Investigator

Central Contact

Lihua Zhang, M.D, Ph.D

✉ zhanglihua@fuwai.com

📞 8613641359895

Frequently Asked Questions

Who can join the NCT06739005 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying CABG-patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06739005 currently recruiting?

Yes, NCT06739005 is actively recruiting participants. Contact the research team at zhanglihua@fuwai.com for enrollment information.

Where is the NCT06739005 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06739005 clinical trial?

NCT06739005 is sponsored by China National Center for Cardiovascular Diseases. The trial plans to enroll 284 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology